Date: 2014-01-14
Type of information: R&D agreement
Compound: DuoBody™ technology platform for the creation of bispecific antibodies
Company: Genmab (Denmark) Lilly (USA - IN)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism: The DuoBody platform is a platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies\' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab\'s DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.
Disease:
Details: * On January 14, 2014, Genmab has announced a research collaboration with Eli Lilly and Company to use and evaluate Genmab's DuoBody technology platform for the creation of bispecific antibodies. Under the collaboration, Lilly will initially evaluate the DuoBody™ technology platform in house. The US group may then consider entering a commercial license agreement if the evaluation is successful.
This agreement will not have a material impact on Genmab\'s financial results and cash position. Genmab has already signed four DuoBody™ collaborations wit Novartis, Kyowa Hakko Kogyo, Janssen Biotech and another undisclosed company.
Financial terms: Financial terms of the agreement have not been disclosed.
Latest news:
